RE:Postponed AGMHere is that post by coldnewfie I referred to before. Hope you don't mind that I reposted coldnewfie.
Post by coldnewfie on Agora
There is more than one deal going on here
in response to
Re: Heading to the bank today..... by
ledenfrog
posted on Oct 21, 16 11:46AM
Use the IP Check tool[?]
I believe that DM has at least two deals that he is working on. The first is the licensing deal that he has openly mentioned for the past year with Resverlogix RVX 208 and the other involves Zenith.
I think with RVX 208, there is no way that DM will settle for anything less then $2.67 (the Hepalink price) because then that Hepalink deal will have to be modified to compensate them for a lower price. The puzzling question is, if there was a deal on the table for the next meeting, why are the insiders purchasing shares?
This would not be allowed by the SEC. Therefore I think a licensing deal is at least six months away.
So why would you postpone the AGM's of both Resverlogix and Zenith? DM has always said that he valued the Shares of Zenith at $1.00 US and did equity raise last year at $1.00 US which establishes that. Since then, there have been advancements in the trials at Zenith and this has been presented at dog and pony shows. So it is my opinion, it is something with Zenith which is the reason for the change in AGM date and not the licensing deal with RVX 208. This is why the insiders at Resverlogix are able to purchase shares in Resverlogix with out causing problems with the SEC.
If DM was to get a partner on one of the Zenith trials, I am sure the Nasdaq would view this as a reasonable platform to issue a listing which DM has stated he is pursuing. With a scenario like this occurring the value of Resverlogix would increase because of the link between the two. JMHO.
---------------
I think this logic is very interesting.
From my perspective there is a lot going on with these 2 companies on both the science and business sides. There are 2 opportunities stuck in my mind.
- One is possible interest by AZ in apabetalone because of the rosuvastatin + apabetalone patent extending out to 2029 as I recall. (e.g. given the post hocs re MACE and all of the MOA results).
- The other is interest by Pfizer re enzalutamide and zen3694 on the mCRPC trial. However, that trial is still in early stages and I don't not believe Zenith is dosing on the zen3694 + enzalutamide has started. However, if the pre-trial tests are of interest to Pfizer and the current progress on the trial is positive there may be interest.
There is a lot going on with these companies and many opportunities including the possibility that some suitor may want to buy into the RVX's and Zenith's 8 year lead in epigenetics.
If there is a Zenith IPO I hope it is on each compound of perhaps all Zenith Epigenetics and not Zenith Capital because I am looking forward to a royalty flow at some point.
Anyway, it is a complex business and there could be many interested parties.
GLTA
Toinv